Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma.

doi:10.4103/jcrt.JCRT_696_16

Back to search

Article

Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma.

Journal of cancer research and therapeutics - 1 Jan 2000

Badri Nabeel, Ngamdu Kyari Sumayin, Torabi Alireza, Guar Sumit

Abstract excerpt

Diffuse large B-cell lymphomas (DLBCL) with MYC translocations combined with translocations involving BCL-2 or BCL-6 are referred to as double-hit lymphomas. These lymphomas are generally refractory to currently available therapies and have a poor prognosis. Primary mediastinal B-cell lymphoma (PMBL) is a rare subtype of DLBCL, which shares clinical, pathologic, and genetic similarities with classical Hodgkin's...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lymphoma, Large B-Cell, Diffuse

Share to Mediastinal Neoplasms

Share to Mutation

Share to Prognosis

Share to Proto-Oncogene Proteins c-bcl-2

Share to Proto-Oncogene Proteins c-myc

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma.PMID 32362635Read

Pathobiology of Primary Mediastinal B-Cell LymphomaSemantic proximity Read

Primary Cutaneous CD30 positive Lymphoproliferative Disorders—Current Therapeutic Approach with Focus on Brentuximab VedotinSemantic proximity Read

Mechanism of action and therapeutic targeting of CD30 molecule in lymphomasSemantic proximity Read

A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy.Semantic proximity Read

Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.Semantic proximity Read

Double-hit lymphomas: current paradigms and novel treatment approaches.Semantic proximity Read

Double-Hit Large B Cell Lymphoma.Semantic proximity Read

Drug therapy for double-hit lymphomaSemantic proximity Read